Divi's Laboratories Limited — Investor Meet, 12-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Divi's Q2FY26 consolidated total income rose 17% YoY to ₹2,860 Cr, with PAT at ₹689 Cr. Custom synthesis now accounts for 56% of sales (generics 44%), and nutraceuticals contributed ₹242 Cr. Export sales were 90%. Management noted stable generic volumes despite pricing pressures, supported by backward integration. Custom synthesis and peptide offerings show strong momentum with projects advancing to commercial scale within 1-2 years. FY26 capex is expected to exceed ₹2,000 Cr, funding new technologies and capacity expansion across units. Management expressed a positive outlook on future growth from the robust project pipeline.